• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Precigen Inc.

    9/18/25 1:30:03 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PGEN alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001091823
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    PRECIGEN, INC.
    SEC File Number
    001-36042
    Address of Issuer
    20374 SENECA MEADOWS PARKWAY
    GERMANTOWN
    MARYLAND
    20876
    Phone
    301-556-9900
    Name of Person for Whose Account the Securities are To Be Sold
    KIRK RANDAL J
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director
    Relationship to Issuer
    10% Stockholder

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Charles Schwab Corp
    3000 Schwab Way
    Westlake � TX � 76262
    500000019625000.0029797292009/18/2025
    Nasdaq


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common01/27/2015Public OfferingIssuerCheckbox not checked47810001/27/2015Cash
    Common07/03/2018Public OfferingIssuerCheckbox not checked311250707/03/2018Cash
    Common08/13/2013Initial Public OfferingIssuerCheckbox not checked89643708/13/2013Cash
    Common12/07/2015Open Market PurchaseIssuerCheckbox not checked22712012/07/2015Cash
    Common12/11/2015Open Market PurchaseIssuerCheckbox not checked11902312/11/2015Cash
    Common05/18/2016Open Market PurchaseIssuerCheckbox not checked3999805/18/2016Cash
    Common08/11/2017Open Market PurcahseIssuerCheckbox not checked12681508/11/2017Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Title of Account: Kapital Joe, LLC - Randal J. Kirk as authorized agent; Using Average of the previous 4 weeks trading volume for volume limitation - Week of 8/18-92,640,600, Week of 8/25-51,961,600, Week of 9/1-31,598,700, Week of 9/8-27,292,900 = 50,873,450 4-week average
    Date of Notice
    09/18/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Randal J. Kirk

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $PGEN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PGEN

    DatePrice TargetRatingAnalyst
    8/15/2025Underweight → Neutral
    Analyst
    3/22/2024Neutral → Underweight
    JP Morgan
    5/23/2023Neutral
    JP Morgan
    11/18/2022$7.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $PGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Precigen Announces Up to $125 Million Non-Dilutive Financing

    $100 million funded at close fortifies balance sheet and supports robust US commercialization of PAPZIMEOS, as well as potential expansion into international markets and the pursuit of pediatric and other HPV-related indications GERMANTOWN, Md., Sept. 2, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that it has entered into a credit facility agreement with investment funds managed by Pharmakon Advisors, LP. "I am pleased to announ

    9/3/25 7:00:00 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright

    GERMANTOWN, Md., Aug. 25, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that Precigen will participate in two upcoming virtual fireside chats hosted by Jennifer Kim of Cantor, and Swayampakula Ramakanth, PhD, of H.C. Wainwright to discuss the recent approval of the first and only FDA-approved therapy for the treatment of adults with recurrent respiratory papillomatosis. Cantor Virtual Fireside ChatAugust 27, 2025, 11 AM – 12 PM ET

    8/25/25 8:05:00 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

    PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with RRP PAPZIMEOS received full approval from the FDA for the treatment of adults with RRP; a confirmatory clinical trial is no longer required RRP is a rare, debilitating, and potentially life-threatening disease caused by chronic HPV 6 or HPV 11 infection, which results in recurrent benign tumors in the respiratory tract; RRP affects an estimated 27,000 adult patients in the USPAPZIMEOS is a non-replicating adenoviral vector-based immunotherapy designed to generate an immune response directed against papilloma cells expressing HPV 6/11—the firs

    8/15/25 7:00:00 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Thomasian Harry Jr. bought $40,016 worth of shares (11,216 units at $3.57), increasing direct ownership by 2% to 468,626 units (SEC Form 4)

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    9/26/25 5:01:54 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Agee Nancy H bought $69,000 worth of shares (15,000 units at $4.60), increasing direct ownership by 7% to 217,841 units (SEC Form 4)

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    9/5/25 5:46:22 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Agee Nancy H bought $98,643 worth of shares (26,005 units at $3.79), increasing direct ownership by 15% to 202,841 units (SEC Form 4)

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    8/29/25 4:21:18 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Thomasian Harry Jr. bought $40,016 worth of shares (11,216 units at $3.57), increasing direct ownership by 2% to 468,626 units (SEC Form 4)

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    9/26/25 5:01:54 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kirk Randal J converted options into 17,385,257 shares and sold $18,653,532 worth of shares (5,000,252 units at $3.73) (SEC Form 4)

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    9/19/25 8:46:14 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by President and CEO Sabzevari Helen

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    9/16/25 7:47:23 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PGEN
    SEC Filings

    View All

    SEC Form 144 filed by Precigen Inc.

    144 - PRECIGEN, INC. (0001356090) (Subject)

    9/29/25 4:12:32 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Precigen Inc.

    EFFECT - PRECIGEN, INC. (0001356090) (Filer)

    9/22/25 12:15:16 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Precigen Inc.

    SCHEDULE 13D/A - PRECIGEN, INC. (0001356090) (Subject)

    9/19/25 8:55:36 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Precigen upgraded by Analyst

    Analyst upgraded Precigen from Underweight to Neutral

    8/15/25 8:13:17 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Precigen downgraded by JP Morgan

    JP Morgan downgraded Precigen from Neutral to Underweight

    3/22/24 7:52:12 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JP Morgan initiated coverage on Precigen

    JP Morgan initiated coverage of Precigen with a rating of Neutral

    5/23/23 7:32:58 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PGEN
    Leadership Updates

    Live Leadership Updates

    View All

    Precigen Reports First Quarter 2025 Financial Results and Business Updates

    PRGN-2012 has the potential to be the first- and best-in-class treatment for RRPCompany's BLA for PRGN-2012 for the treatment of adults with RRP is under priority review by the FDA with a PDUFA target action date set for August 27, 2025RRP is a rare, debilitating chronic disease with approximately 27,000 adult patients in the US and more than 125,000 patients outside of the USCompany continues to rapidly advance commercial and manufacturing readiness campaign in anticipation of 2025 commercial launch Company and Recurrent Respiratory Papillomatosis Foundation to host the 2025 International RRP Awareness Day on June 11Cash, cash equivalents, and investments of $81.0 million as of March 31, 20

    5/14/25 4:05:00 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

    – International event will raise awareness and bring together RRP patients, caregivers, and the healthcare community supporting them –– Recurrent respiratory papillomatosis is a rare, debilitating, chronic disease that impacts both children and adults and is mainly driven by HPV 6/11 infection –– There is no FDA-approved therapeutic for the treatment of RRP, and the current standard-of-care is repeated surgeries, which do not address the underlying cause of disease and are associated with significant morbidity and risk of irreversible injury – GERMANTOWN, Md., April 16, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovativ

    4/16/25 8:05:00 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch

    –  Company strengthens focus on building and optimizing commercial readiness and pre-launch activities for PRGN-2012 in recurrent respiratory papillomatosis – GERMANTOWN, Md., July 23, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the appointment of Phil Tennant as the Company's chief commercial officer. Mr. Tennant will be responsible for commercial strategy and execution across US and global markets. His initial focus will be on driving commercial readiness activities for the potential launch of the first- and best-in-class PRGN-2012 Aden

    7/23/24 8:01:00 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PGEN
    Financials

    Live finance-specific insights

    View All

    Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

    PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with RRP PAPZIMEOS received full approval from the FDA for the treatment of adults with RRP; a confirmatory clinical trial is no longer required RRP is a rare, debilitating, and potentially life-threatening disease caused by chronic HPV 6 or HPV 11 infection, which results in recurrent benign tumors in the respiratory tract; RRP affects an estimated 27,000 adult patients in the USPAPZIMEOS is a non-replicating adenoviral vector-based immunotherapy designed to generate an immune response directed against papilloma cells expressing HPV 6/11—the firs

    8/15/25 7:00:00 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

    GERMANTOWN, Md., March 13, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release full year 2024 financial results and provide business updates on Wednesday, March 19, 2025. The Company will host a conference call to discuss results that day at 4:30 PM ET. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants are asked to dial in 10-15 minu

    3/13/25 8:05:00 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

    GERMANTOWN, Md., Dec. 27, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that it has entered into a securities purchase agreement for the sale of its 8.00% Series A Convertible Perpetual Preferred Stock (Preferred Stock) in a private placement. Precigen anticipates gross proceeds from the private placement of $79.0 million before deducting offering expenses. In addition, the investors will have rights to exercise warrants to purchase 52,666,669 shares of Precigen's common stock at an exercise price of $0.75 per share (Warrants). The offering

    12/27/24 9:00:00 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Precigen Inc.

    SC 13D/A - PRECIGEN, INC. (0001356090) (Subject)

    8/13/24 4:05:10 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Precigen Inc. (Amendment)

    SC 13D/A - PRECIGEN, INC. (0001356090) (Subject)

    5/3/24 8:01:15 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Precigen Inc. (Amendment)

    SC 13G/A - PRECIGEN, INC. (0001356090) (Subject)

    2/27/24 1:48:40 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care